We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > alpha-mannosidosis

News List

EU green light for Chiesi’s Lamzede pharmatimes
July 18, 2018
European regulators have green-lighted Chiesi’s Lamzede as the first long-term enzyme replacement therapy to treat non-neurological manifestations in patients with mild to moderate alpha-mannosidosis.
NICE rejects Chiesi’s Lamzede pharmatimes
July 11, 2018
It is currently looking unlikely that Chiesi’s Lamzede will become routinely available on the NHS for patients with alpha-mannosidosis, after cost-regulators issued a preliminary rejection of the drug.
Enzyme replacement therapy to treat alpha-mannosidosis europeanpharmaceuticalreview
January 30, 2018
The EMA has recommended granting a marketing authorisation in the EU for Lamzede a long-term enzyme replacement therapy for alpha-mannosidosis…